Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02940262 · ClinicalTrials.gov registry record · Phase 3
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
A Phase 3 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,138
- Enrollment target
- 1
- Study location
NCT02940262: Completed Phase 3 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
NCT02940262 is a Phase 3 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 1,138 participants, above the 207-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (450% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02940262, a Phase 3 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,138 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent) in patients after initial therapy. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET/CT, may help doctors detect tumors that have come back after initial therapy.
Primary Outcome
Confirmed by histopathology/biopsy, clinical and conventional imaging follow-up. Will be calculated and reported along with the corresponding two-sided 95% confidence intervals. The confidence intervals will be constructed using the Wilson score method.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- RADIATION Gallium Ga 68 Gozetotide
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,138 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2021-06-18 |
| Phase | Phase 3 |
What the finished NCT02940262 record still lists
NCT02940262 is an interventional study that assigns participants to a tested intervention. Its 1,138 participants enrollment target places it among the larger protocols in the corpus, above the 207-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (450% higher).
The record links to 2 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Positron Emission Tomography is the first listed.
NCT02940262 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02940262 about?
NCT02940262 is a clinical study titled "Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy". This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent) in patients after initial therapy. Diagnostic procedures, such as gall...
What is the current status of trial NCT02940262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,138 participants. The study started on 2016-09-15. Estimated completion is 2021-06-18.
What conditions does trial NCT02940262 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma.
What interventions are being tested in trial NCT02940262?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Gallium Ga 68 Gozetotide (RADIATION).
Who is sponsoring clinical trial NCT02940262?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02940262 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02940262's enrollment target sits among peer trials
1,138 5th of 99 higher than 95 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RECRUITING · Phase 3
-
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RECRUITING · Phase 3
-
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RECRUITING · Phase 3
-
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
RECRUITING · Phase 3
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI